NN
NNNN.US Anbio Biotechnology Class A Ordinary Shares
- Market cap
- USD 170M
- P/E
- 25.9x
- P/B
- 5.68x
- ROE
- 40.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is NNNN.US undervalued?
Graham numberNNNN.US trades 155.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anbio Biotechnology Class A Ordinary Shares fundamental analysis
No fundamental analysis for Anbio Biotechnology Class A Ordinary Shares yet.
Anbio Biotechnology Class A Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care t…
Full company profileAnbio Biotechnology Class A Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anbio Biotechnology Class A Ordinary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 4.43M | 23.5M | 6.71M | 8.19M | 8.65M | 19.0M |
| Gross Profit | 2.54M | 12.6M | 3.36M | 5.89M | 7.54M | 15.4M |
| Operating Income | 2.46M | 10.2M | 1.96M | 2.00M | 5.77M | 11.2M |
| EBITDA | 2.54M | 10.0M | 2.27M | 2.00M | 5.77M | 11.2M |
| Net Income | 2.54M | 10.0M | 2.25M | 2.37M | 6.40M | 12.2M |
| EPS | 0.03 | 0.07 | 0.01 | 0.06 | 0.15 | 0.28 |
| Balance Sheet | ||||||
| Total Assets | 4.92M | 14.0M | 15.8M | 18.9M | 30.2M | 30.2M |
| Total Liabilities | 2.38M | 1.41M | 993K | 1.73M | 87.8K | 87.8K |
| Shareholders' Equity | 2.54M | 12.5M | 14.8M | 17.2M | 30.2M | 30.2M |
| Cash & Short-term Investments | 4.18M | 8.67M | 9.69M | 11.8M | 11.9M | 11.9M |
| Cash Flow | ||||||
| Operating Cash Flow | 4.18M | 4.45M | 898K | 2.08M | -6.74M | - |
| Capital Expenditure | 0.00 | 2.88 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 4.18M | 4.45M | 898K | 2.08M | -6.74M | - |
| Ratios | ||||||
| ROE | 100.0% | 79.8% | 15.2% | 13.8% | 21.2% | 40.3% |
| ROA | 51.6% | 71.7% | 14.3% | 12.5% | 21.2% | 40.2% |
| Net Profit Margin | 57.3% | 42.5% | 33.6% | 29.0% | 74.1% | 64.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Anbio Biotechnology Class A Ordinary Shares dividends
Anbio Biotechnology Class A Ordinary Shares has not paid dividends in the last 5 fiscal years.
Who owns Anbio Biotechnology Class A Ordinary Shares
- Insiders 4.79%
- Institutions 5.06%
- Public & others 90.16%
- Shares outstanding 43.9M
- Free float 39.7M
Top funds holding NNNN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Intl Sm Cp ETF | 25.7K | 0.06% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 22.2K | 0.05% | -16.93% | Aug 2026 |
Top institutions holding NNNN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 26.7K | 0.06% | +3.78% | Jun 2026 |
| Bank of America Corp | 13.4K | 0.03% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 11.8K | 0.03% | +13.46% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 11.5K | 0.03% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 7.23K | 0.02% | -1.46% | Jun 2026 |
| UBS Group AG | 828.00 | 0.00% | -86.94% | Jun 2026 |
| EverSource Wealth Advisors, LLC | 187.00 | 0.00% | -29.70% | Jun 2026 |
| Advisor Group Holdings, Inc. | 77.00 | 0.00% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 53.00 | 0.00% | 0.00% | Jun 2026 |
| Bare Financial Services Inc | 15.00 | 0.00% | 0.00% | Jun 2026 |
| Larson Financial Group, LLC | 5.00 | 0.00% | 0.00% | Jun 2026 |
| Silver Grove Financial Group, Inc. | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Ronald Blue Trust, Inc. | 0.00 | 0.00% | -100.00% | Jun 2026 |
Anbio Biotechnology Class A Ordinary Shares company profile
- Company name
- Anbio Biotechnology Class A Ordinary Shares
- Ticker
- NNNN.US
- ISIN
- KYG0367B1059
- Exchange
- USA Stocks
- Listed since
- Feb 19, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 27
- Fiscal year end
- December
- Address
- Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, Germany, 60327
- Phone
- 49 698 7003 9170
- Website
- anbiobiotechnology.com
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Anbio Biotechnology Class A Ordinary Shares management
3- Mr. Michael Lau M.B.A., Ph.D.Chief Executive Officer · born 1982
- Ms. Suki Song CPAChief Financial Officer · born 1983
- Mr. Chris TianChief Business Officer · born 1991